

SUPPLEMENTARY MATERIAL

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies

Nory Mariño-Ocampo ^{1,∞}, Diego F. Rodríguez ^{1,∞}, Daniel Guerra Díaz ¹, Daniel Zúñiga-Núñez ¹, Yorley Duarte ², Denis Fuentealba^{1,*} and Flavia C. Zacconi ^{1,3,4,5*}

1 Escuela de Química, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.

2 Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago 8370035, Chile.

3 Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.

4 Centro de Investigaciones en Nanotecnología y Materiales Avanzados, CIEN-UC, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.

5 Center for Nanomedicine, Diagnostic & Drug Development (ND3), Universidad de Talca, Talca 3460000, Chile.

[∞] Contributed equally to this work: Nory Mariño-Ocampo and Diego F. Rodríguez.

* Correspondence: dlfuente@uc.cl (D.F.), fzacconi@uc.cl (F.C.Z.)

List of content

- Figure S1.** Fluorescence quenching spectra of HSA in the presence of edoxaban tosylate at 298 K. Samples measurements were recorded in 0.10 M Tris-HCl buffer pH 7.4 and 0.10 M NaCl, $\lambda_{\text{ex}}=295$ nm, and, $\lambda_{\text{em}}=350$ nm.....3S
- Figure S2.** Fluorescence quenching spectra of HSA in the presence of betrixaban maleate at 298 K. Samples measurements were recorded in 0.10 M Tris-HCl buffer pH 7.4 and 0.10 M NaCl, $\lambda_{\text{ex}}=295$ nm, and, $\lambda_{\text{em}}=350$ nm.....3S
- Figure S3.** The Stern-Volmer curves for the quenching of HSA by: a) edoxaban tosylate hydrate and b) betrixaban maleate at 298 K and 310 K.....4S
- Table S1.** Stern-Volmer quenching constant (K_{sv}) of HSA with anticoagulants at two temperatures.....4S

5. Table S2. Fluorescence lifetimes and pre-exponential factors of HSA (2 μ M) with AP at different concentrations (0-12 μ M) at 293 K in under aerated conditions. The excitation wavelength was 279 nm.....	4S
6. Table S3. Fluorescence lifetimes and pre-exponential factors of HSA (2 μ M) with RV at different concentrations (0-12 μ M) at 293 K in under aerated conditions. The excitation wavelength was 279 nm.....	5S
7. Table S4. Fluorescence lifetimes and pre-exponential factors of HSA (2 μ M) with ED at different concentrations (0-12 μ M) at 293 K in under aerated conditions. The excitation wavelength was 279 nm.....	5S
8. Table S5. Fluorescence lifetimes and pre-exponential factors of HSA (2 μ M) with BE at different concentrations (0-12 μ M) at 293 K in under aerated conditions. The excitation wavelength was 279 nm.....	6S
9. Figure S4. ITC data for a titration of 696 μ M HSA into AP solution (50 μ M) in phosphate buffer 10 mM, pH = 7.4. <i>Top</i> : Raw data; <i>bottom</i> : Integrated heat effects per injection as a function of molar ratio (fitted to a one site model).....	6S
10. Figure S5. ITC data for a titration of 1.58 mM BE maleate into HSA solution (100 μ M) in phosphate buffer 10 mM, pH = 7.4. <i>Top</i> : Raw data; <i>bottom</i> : Integrated heat effects per injection as a function of molar ratio (fitted to a one site model).....	7S




Figure S1. Fluorescence quenching spectra of HSA in the presence of edoxaban tosylate at 298 K. Samples measurements were recorded in 0.10 M Tris-HCl buffer pH 7.4 and 0.10 M NaCl, $\lambda_{\text{ex}}=295$ nm, and $\lambda_{\text{em}}=350$ nm.




Figure S2. Fluorescence quenching spectra of HSA in the presence of betrixaban maleate at 298 K. Samples measurements were recorded in 0.10 M Tris-HCl buffer pH 7.4 and 0.10 M NaCl, $\lambda_{\text{ex}}=295$ nm, and $\lambda_{\text{em}}=350$ nm.




Figure S3. The Stern-Volmer curves for the quenching of HSA by: a) edoxaban tosylate hydrate and b) betrixaban maleate at 298 K and 310 K.

Table S1. Stern-Volmer quenching constant (K_{sv}) of HSA with anticoagulants at two temperatures.

Anticoagulant	$K_{sv} (\times 10^4 \text{ M}^{-1})$ 298 K	$K_{sv} (\times 10^4 \text{ M}^{-1})$ 310 K
EDT	1.79±0.03	1.27±0.02
BEM	1.59±0.05	1.36±0.03

Table S2. Fluorescence lifetimes and pre-exponential factors of HSA (2 μM) with AP at different concentrations (0-12 μM) at 293 K in under airedated conditions. The excitation wavelength was 279 nm.

Probe	τ_1 (ns)	A_1	τ_2 (ns)	A_2	χ^2	$\langle \tau_F \rangle$
HSA	3.01	0.41	6.80	0.59	1.21	5.25
AP@HSA (1:1)	3.22	0.45	7.01	0.55	1.10	5.30
AP@HSA (1:2)	2.93	0.41	6.83	0.59	1.06	5.23
AP@HSA (1:4)	2.73	0.38	6.69	0.62	1.17	5.19
AP@HSA (1:6)	2.86	0.42	6.83	0.58	1.13	5.16

Table S3. Fluorescence lifetimes and pre-exponential factors of HSA (2 μM) with RV at different concentrations (0-12 μM) at 293 K in under aireated conditions. The excitation wavelength was 279 nm.

Probe	τ_1 (ns)	A ₁	τ_2 (ns)	A ₂	χ^2	$\langle\tau_F\rangle$
HSA	3.01	0.41	6.80	0.59	1.21	5.25
RV@HSA (1:1)	3.00	0.40	6.80	0.60	1.13	5.28
RV@HSA (1:2)	2.98	0.41	6.82	0.59	1.09	5.25
RV@HSA (1:4)	2.98	0.42	6.85	0.58	0.99	5.22
RV@HSA (1:6)	2.94	0.43	6.87	0.57	1.12	5.18

Table S4. Fluorescence lifetimes and pre-exponential factors of HSA (2 μM) with ED at different concentrations (0-12 μM) at 293 K in under aireated conditions. The excitation wavelength was 279 nm.

Complex	τ_1 (ns)	A ₁	τ_2 (ns)	A ₂	χ^2	$\langle\tau_F\rangle$
HSA	3.01	0.41	6.80	0.59	1.21	5.25
ED@HSA (1:1)	2.99	0.39	6.80	0.61	1.13	5.31
ED@HSA (1:2)	2.93	0.40	6.80	0.60	1.16	5.25
ED@HSA (1:4)	2.71	0.40	6.71	0.60	1.16	5.11
ED@HSA (1:6)	2.94	0.44	6.88	0.54	1.20	5.01

Table S5. Fluorescence lifetimes and pre-exponential factors of HSA (2 μM) with BE at different concentrations (0-12 μM) at 293 K in under aireated conditions. The excitation wavelength was 279 nm.

Complex	τ_1 (ns)	A ₁	τ_2 (ns)	A ₂	χ^2	$\langle\tau_F\rangle$
HSA	3.01	0.41	6.80	0.59	1.21	5.25
BE@HSA (1:1)	3.03	0.39	6.78	0.61	1.10	5.32
BE@HSA (1:2)	2.89	0.38	6.78	0.62	1.10	5.30
BE@HSA (1:4)	2.86	0.38	6.73	0.62	1.09	5.26
BE@HSA (1:6)	2.60	0.35	6.61	0.65	1.09	5.21




Figure S4. ITC data for a titration of 696 μM HSA into AP solution (50 μM) in phosphate buffer 10 mM, pH = 7.4. *Top:* Raw data; *bottom:* Integrated heat effects per injection as a function of molar ratio (fitted to a one-site model).




Figure S5. ITC data for a titration of 1.58 mM BE maleate into HSA solution (100 μ M) in phosphate buffer 10 mM, pH = 7.4. *Top*: Raw data; *bottom*: Integrated heat effects per injection as a function of molar ratio (fitted to a one-site model).